New cancer drug shows promise in early trial for advanced tumors
NCT ID NCT04823897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called CCI-001 in people with advanced solid tumors that have come back or spread. The main goals are to check the drug's safety and find the best dose. About 70 participants will receive CCI-001 alone or with standard chemotherapy drugs like gemcitabine or carboplatin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER: RECURRENT AND/OR METASTATIC SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••